BACKGROUND AND PURPOSE: Changes in diet and lifestyle factors are frequently recommended for persons with irritable bowel syndrome (IBS). It is unknown whether these recommendations alter the gut microbiome and/or whether baseline microbiome predicts improvement in symptoms and quality of life following treatment. Therefore, the purpose of this study was to explore if baseline gut microbiome composition predicted response to a Comprehensive Self-Management (CSM) intervention and if the intervention resulted in a different gut microbiome composition compared to usual care. METHODS: Individuals aged 18-70 years with IBS symptoms ≥6 months were recruited using convenience sampling. Individuals were excluded if medication use or comorbidities would influence symptoms or microbiome. Participants completed a baseline assessment and were randomized into the eight-session CSM intervention which included dietary education and cognitive behavioral therapy versus usual care. Questionnaires included demographics, quality of life, and symptom diaries. Fecal samples were collected at baseline and 3-month post-randomization for 16S rRNA-based microbiome analysis. RESULTS: Within the CSM intervention group (n = 30), Shannon diversity, richness, and beta diversity measures at baseline did not predict benefit from the CSM intervention at 3 months, as measured by change in abdominal pain and quality of life. Based on both alpha and beta diversity, the change from baseline to follow-up microbiome bacterial taxa did not differ between CSM (n = 25) and usual care (n = 25). CONCLUSIONS AND INFERENCES: Baseline microbiome does not predict symptom improvement with CSM intervention. We do not find evidence that the CSM intervention influences gut microbiome diversity or composition over the course of 3 months.
BACKGROUND AND PURPOSE: Changes in diet and lifestyle factors are frequently recommended for persons with irritable bowel syndrome (IBS). It is unknown whether these recommendations alter the gut microbiome and/or whether baseline microbiome predicts improvement in symptoms and quality of life following treatment. Therefore, the purpose of this study was to explore if baseline gut microbiome composition predicted response to a Comprehensive Self-Management (CSM) intervention and if the intervention resulted in a different gut microbiome composition compared to usual care. METHODS: Individuals aged 18-70 years with IBS symptoms ≥6 months were recruited using convenience sampling. Individuals were excluded if medication use or comorbidities would influence symptoms or microbiome. Participants completed a baseline assessment and were randomized into the eight-session CSM intervention which included dietary education and cognitive behavioral therapy versus usual care. Questionnaires included demographics, quality of life, and symptom diaries. Fecal samples were collected at baseline and 3-month post-randomization for 16S rRNA-based microbiome analysis. RESULTS: Within the CSM intervention group (n = 30), Shannon diversity, richness, and beta diversity measures at baseline did not predict benefit from the CSM intervention at 3 months, as measured by change in abdominal pain and quality of life. Based on both alpha and beta diversity, the change from baseline to follow-up microbiome bacterial taxa did not differ between CSM (n = 25) and usual care (n = 25). CONCLUSIONS AND INFERENCES: Baseline microbiome does not predict symptom improvement with CSM intervention. We do not find evidence that the CSM intervention influences gut microbiome diversity or composition over the course of 3 months.
Authors: Jalpa A Doshi; Qian Cai; Jessica L Buono; William M Spalding; Phil Sarocco; Hiangkiat Tan; Judith J Stephenson; Robyn T Carson Journal: J Manag Care Spec Pharm Date: 2014-04
Authors: Jeffrey M Lackner; James Jaccard; Laurie Keefer; Darren M Brenner; Rebecca S Firth; Gregory D Gudleski; Frank A Hamilton; Leonard A Katz; Susan S Krasner; Chang-Xing Ma; Christopher D Radziwon; Michael D Sitrin Journal: Gastroenterology Date: 2018-04-25 Impact factor: 22.682
Authors: Hsiu-Feng Hsueh; Monica E Jarrett; Kevin C Cain; Robert L Burr; Wimon Deechakawan; Margaret M Heitkemper Journal: Gastroenterol Nurs Date: 2011 Mar-Apr Impact factor: 0.978
Authors: M Vodička; P Ergang; T Hrnčíř; A Mikulecká; P Kvapilová; K Vagnerová; B Šestáková; A Fajstová; P Hermanová; T Hudcovic; H Kozáková; J Pácha Journal: Brain Behav Immun Date: 2018-07-07 Impact factor: 7.217
Authors: A P Allen; W Hutch; Y E Borre; P J Kennedy; A Temko; G Boylan; E Murphy; J F Cryan; T G Dinan; G Clarke Journal: Transl Psychiatry Date: 2016-11-01 Impact factor: 6.222
Authors: Ruth Ann Luna; Numan Oezguen; Miriam Balderas; Alamelu Venkatachalam; Jessica K Runge; James Versalovic; Jeremy Veenstra-VanderWeele; George M Anderson; Tor Savidge; Kent C Williams Journal: Cell Mol Gastroenterol Hepatol Date: 2016-12-11